CRISPR-edited cell lines are a useful tool to validate your antibodies before you start an experiment. They ensure you are using high quality reagents, so you can be confident in your results. Here we explain how you can use our edited cell lines for validation, the challenges to be aware of and how we can help you overcome them.
CRISPR technology now allows genes and molecular pathways to be examined with greater definition. We look at how knockout cell lines, either together with gene rescue and replication of disease mutations or as an independent cell model, can be used to validate your research and extend your findings
Revealing the role of E3 ubiquitin ligases in DNA damage repair. One of the diverse new uses for the HAP1 cell line, one that has begun to draw significant attention, is in the field of DNA damage repair. A recent paper from Minoru Takata's group highlights this important application of this relatively new tool.
Cancer fusion genes are hybrid genes that produce abnormal proteins believed to catalyze further cancer growth and increase invasiveness. Here we highlight novel research using CRISPR gene editing to specifically target cancer fusion genes, which could offer many potential therapeutic applications.
SHERLOCK is exciting because it represents a sensitive approach to detect mutations, much like PCR, but it does not require a thermocycler and could work as a bedside test.
The cellular DNA damage response (DDR) is an essential safeguard against cancer. Upon activation, the DDR can limit tumor progression at the early stages by inducing senescence or cell death. When this defense fails tumors are able to develop. However, with time, tumors accumulate more mutations in DNA repair proteins as cancers progress. The efficiency of DDR plays an essential role in the effectivity of cytotoxic treatments. Currently much research is focused on identifying the DDR mechanisms involved in cancers and how these dysfunctional processes can be utilized against tumor growth.
Knockout and tagged gene-editing can create cell lines ideal for antibody validation. Using CRISPR CAS technology, Horizon developed a streamlined process to cut production time. Read more in our interview with Lead Scientist Daniel Lackner.
In a paper published on Nature.com in Scientific Reports, Horizon Discovery have conducted a detailed analysis of CRISPR-Cas9 sensitivity (drop-out) screening to come up with a highly improved and optimized platform. In our analysis, we used a custom ultra-complex sgRNA library and capitalized on Horizon's streamlined screening pipeline to evaluate fundamental aspects of functional genomic screening.
The scientists at Horizon Discovery have published a robust and precise approach to generating translocations. This advancement facilitates the generation of relevant cell line models for oncology research.